Oxigran Plus Tablet SR is a sustained-release formulation combining Propranolol 40 mg and Flunarizine 10 mg, designed for the management of migraine prophylaxis and certain cardiovascular conditions. Propranolol, a non-selective beta-adrenergic blocker, exerts its therapeutic effect by reducing heart rate, myocardial contractility, and blood pressure, thereby decreasing cardiac workload and oxygen demand. It is effective in preventing migraine attacks by stabilizing vascular tone and reducing sympathetic nervous system activity. Flunarizine, a calcium channel blocker with antihistaminic properties, inhibits the influx of calcium ions into vascular smooth muscle and neuronal cells, promoting cerebral vasodilation and reducing neuronal excitability, which contributes to its efficacy in migraine prevention and treatment of vertigo. The sustained-release formulation ensures a steady plasma concentration, improving patient compliance and minimizing peak-related side effects. Oxigran Plus is indicated for patients requiring combined beta-blockade and calcium channel blockade for migraine prophylaxis, especially in those with concomitant hypertension or angina. It should be used under medical supervision with caution in patients with asthma, bradycardia, or depression. Common adverse effects include fatigue, dizziness, and gastrointestinal discomfort. Regular monitoring of cardiovascular status is recommended during therapy.